Clinical Trial Update: Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating seviteronel in patients with castration-resistant prostate cancer progressing on enzalutamide or abiraterone.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Seviteronel (seviteronel)

Snippet

Sponsor: Innocrin Pharmaceutical | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED